NCT01256138

Brief Summary

Allogene MSCs transplantation will be performed in patients with chronic liver diseases through portal vein by ultrasound guiding and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 7, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 8, 2010

Completed
Last Updated

December 8, 2010

Status Verified

October 1, 2010

First QC Date

December 7, 2010

Last Update Submit

December 7, 2010

Conditions

Allogene TransplantationChronic Liver Diseases PatientsThrough Portal Vein by Ultrasound Guiding

Keywords

Allogene MSCstransplantationchronic liver diseasesportal vein

Outcome Measures

Primary Outcomes (1)

  • Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation

    1-8 weeks

Study Arms (2)

transplantation

control

Eligibility Criteria

Age15 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease and so on.

You may qualify if:

  • chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease.
  • age: 15-65 years old.

You may not qualify if:

  • pregnant women and women in lactation.
  • other systems and organs disfunction
  • space-occupying lesion were found in liver.
  • concurrent infection with HIV and other immunodeficiency diseases.
  • DIC and active bleeding were confirmed.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510630, China

RECRUITING

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 7, 2010

First Posted

December 8, 2010

Study Start

October 1, 2010

Last Updated

December 8, 2010

Record last verified: 2010-10

Locations

CN(1)